RxDoctor Payments Data

Jenna Bernard, OD

Optometrist · Medina, OHNPI 1417696873

Payments from drug & device makers

$7,625in general payments, 2019–2025

Across 199 payments — averaging $38.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Johnson & Johnson Vision Care, Inc.$2K
  • Biotissue Holdings Inc.$1K
  • Tarsus Pharmaceuticals, Inc.$442
  • AbbVie$337
  • Mallinckrodt Hospital Products Inc.$246
  • plus $1K from 11 others
$690in research payments, 2019–2025

Across 23 payments — averaging $30.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Notal Vision, Inc.$690

What the payments were for

  • Speaking & faculty fees$180%
  • Travel & lodging$1,65922%
  • Food & beverage$5,84877%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,625 in reported general payments places this provider in the 95th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$30,282
Medicare patients
171
Services billed
1,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod12$8,984
MieboPerfluorohexyloctane/Pf11$7,895
Brimonidine Tartrate11$1,828
Prednisolone Acetate15$568
Latanoprost41$326
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$226
Timolol Maleate16$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta, Miebo$85$16,87923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Medina

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →